Note: Ingredients listed on restricted chemical lists
EC/CAS
204-617-8/123-31-9
Name of the chemical
1,4-Dihydroxybenzol (790/2009)
Concentration
>=0,025-<
General Information
Version
3.5
Revision date
2022-03-15
Product name
Industrial Superglue GP
Emergency telephone
+44 870 190 6777
Icons in SDS
Company Information
company name
Everbuild - A Sika Company
e-mail address of the competent person responsible for the Safety Data Sheet
everbuild.sds@uk.sika.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H315, H319, H335
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Classification
Signal word
Warning
Hazard statements
H315 Causes skin irritation. H319 Causes serious eye irritation. H335 May cause respiratory irritation.
Prevention
P261 Avoid breathing mist or vapours. P264 Wash skin thoroughly after handling. P280 Wear protective gloves/ eye protection/ face protection.
Response
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell. P337 + P313 If eye irritation persists: Get medical advice/ attention.
Storage
P403 + P233 Store in a well-ventilated place. Keep con- tainer tightly closed.
Hazardous Ingredients
ethyl 2-cyanoacrylate
Additional information
EUH202 Cyanoacrylate. Danger. Bonds skin and eyes in seconds. Keep out of the reach of children.
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have en- docrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regula- tion (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
